AMEX · ATNM
Healthcare · Biotechnology
$1.20
Down-$0.09 (-7.50%)
Updated Oct 6, 2026, 8:40 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ATNM
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ATNM closed at $1.20 after 20 trading sessions, down 2.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.16 | $1.24 | $1.16 | $1.20 | 115.03K |
| Oct 2, 2026 | $1.15 | $1.19 | $1.12 | $1.17 | 81.8K |
| Oct 1, 2026 | $1.11 | $1.15 | $1.11 | $1.15 | 90.83K |
| Sep 30, 2026 | $1.14 | $1.20 | $1.10 | $1.12 | 95.13K |
| Sep 29, 2026 | $1.17 | $1.17 | $1.14 | $1.14 | 62.02K |
| Sep 28, 2026 | $1.18 | $1.20 | $1.17 | $1.18 | 75.37K |
| Sep 25, 2026 | $1.19 | $1.205 | $1.18 | $1.20 | 28.42K |
| Sep 24, 2026 | $1.19 | $1.25 | $1.18 | $1.19 | 85.94K |
| Sep 23, 2026 | $1.17 | $1.21 | $1.16 | $1.18 | 130.43K |
| Sep 22, 2026 | $1.18 | $1.22 | $1.17 | $1.17 | 54.49K |
| Sep 21, 2026 | $1.24 | $1.24 | $1.166 | $1.20 | 99.38K |
| Sep 18, 2026 | $1.18 | $1.23 | $1.18 | $1.22 | 146.21K |
| Sep 17, 2026 | $1.26 | $1.26 | $1.18 | $1.19 | 57.03K |
| Sep 16, 2026 | $1.26 | $1.275 | $1.24 | $1.24 | 59.77K |
| Sep 15, 2026 | $1.28 | $1.32 | $1.25 | $1.25 | 96.17K |
| Sep 14, 2026 | $1.41 | $1.4183 | $1.25 | $1.28 | 301.51K |
| Sep 11, 2026 | $1.31 | $1.42 | $1.285 | $1.40 | 242.66K |
| Sep 10, 2026 | $1.25 | $1.34 | $1.2301 | $1.31 | 226.76K |
| Sep 9, 2026 | $1.24 | $1.305 | $1.22 | $1.23 | 366.57K |
| Sep 8, 2026 | $1.06 | $1.25 | $1.06 | $1.23 | 574.18K |
The latest Smart Investors Daily articles mentioning ATNM.
Company
Market Activity
Research & News
ATNM research
Company profile and research snapshot.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 31, 2026 | Stephens & Co. | Overweight | — |
| Jun 24, 2025 | HC Wainwright & Co. | Buy | — |
| May 12, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 28, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 15, 2026
By John Vandermosten, CFA NYSE: ATNM READ THE FULL ATNM RESEARCH REPORT We are initiating coverage of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) and assign a valuation of $4.00 per share. This valuation is based on our estimates for successful development, approval, and commercialization of ATNM-400 in solid tumors, Actimab-A, Iomab-ACT, and Iomab-B in acute myeloid leukemia (AML), solid tumors,
Yahoo · Sep 4, 2026
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sandesh Seth, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14-16, 2026, in New York, NY. Company management will also be available for one-on-one meetings with investors.
Yahoo · Aug 14, 2026
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.
Benzinga · Aug 14, 2026
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ATNM.
